Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
Key Financial Performance
Operating Expenses Total operating expenses, net, were approximately $2.9 million in Q3 2025, compared to $6.6 million in Q3 2024, reflecting a significant reduction due to organizational changes and cost reduction measures.
Income from Discontinued Operations Income from discontinued operations net was approximately $7.9 million in Q3 2025, compared to a loss of $1.5 million in Q3 2024. This includes proceeds from the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL.
Revenues Revenues for the 9 months ending September 30, 2025, were approximately $3.5 million, compared to $4 million in the same period of 2024, a decrease primarily driven by lower revenue from AgPlenus' activity, including a one-time payment from Bayer in Q1 2024, partially offset by increased seed sales by Casterra.
Research and Development Expenses R&D expenses for the 9 months ending September 30, 2025, were approximately $5.9 million, compared to $9.8 million in the same period of 2024, primarily due to reduced activities in Biomica and the discontinuation of Canonic's operations.
Sales and Marketing Expenses Sales and marketing expenses for the 9 months ending September 30, 2025, were approximately $1.1 million, compared to $1.6 million in the same period of 2024, mainly due to headcount reductions across subsidiaries.
Operating Loss Total operating loss for the 9 months ending September 30, 2025, was approximately $8.8 million, compared to $15.3 million in the same period of 2024, mainly due to decreased activities in subsidiaries and Evogene.
Cash and Short-term Bank Deposits As of September 30, 2025, the company's cash and short-term bank deposit balance was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL.
Net Loss Net loss for the 9 months ending September 30, 2025, was approximately $2.5 million, compared to $18 million in the same period of 2024, a significant improvement due to reduced operating expenses, income from discontinued operations, and increased financial income.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ChemPass AI: Evogene's proprietary generative AI tech-engine designed to create novel small molecules for pharmaceutical and agriculture industries. It focuses on high potency, novelty, and multi-parameter excellence.
Agriculture Market: AgPlenus, a subsidiary of Evogene, targets the $79 billion agriculture market, focusing on herbicides, insecticides, and fungicides. Collaborations with Bayer and Corteva aim to develop new herbicides with novel modes of action.
Pharmaceutical Market: Evogene is leveraging ChemPass AI to target the $780 billion pharmaceutical market, focusing on small molecule-based drugs. The AI drug discovery market is expected to grow to $190 billion by 2034.
Cost Reduction: Evogene implemented a cost reduction plan, reducing operating expenses significantly. Total operating expenses decreased to $2.9 million in Q3 2025 from $6.6 million in Q3 2024.
Subsidiary Sales: Evogene sold the majority of Lavie Bio's activities and MicroBoost AI for Ag to ICL, generating $7.9 million in Q3 2025.
Strategic Shift: Evogene transitioned to focus on computational chemistry and generative AI for small molecule design in pharmaceuticals and agriculture. This includes organizational restructuring and cost reductions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Impact of Israel-Hamas War: The ongoing war between Israel and Hamas poses significant risks to the company's operations in Southern Israel. This includes potential disruptions due to the calling up of reserve soldiers, economic instability caused by war-related debt, and uncertainties regarding the security of operations.
Revenue Decline: Revenues for the first 9 months of 2025 decreased to $3.5 million from $4 million in the same period of 2024, primarily due to lower revenue from AgPlenus' activity and reduced seed sales by Casterra.
Reduced R&D and Operational Activities: The company has significantly reduced R&D expenses and operational activities, including the discontinuation of Canonic's operations and reduced activities in Biomica. While this reduces costs, it may limit future innovation and growth.
Dependence on Strategic Collaborations: The company's strategy heavily relies on collaborations with major players like Bayer and Corteva. Any disruption or failure in these partnerships could adversely impact the company's progress and financials.
Market Challenges in Agriculture: The agriculture industry faces challenges such as increased pest resistance, stringent regulatory requirements, and a decreased rate of new pesticide discoveries, which could impact AgPlenus' ability to develop successful products.
Pharma Industry Risks: The development of small molecule-based drugs is expensive, lengthy, and has a low success rate (3%-10%). This poses a risk to the company's new strategy in the pharmaceutical sector.
Cash Flow and Financial Sustainability: The company reported a cash balance of $16 million as of Q3 2025, with a cash usage of $3.5 million in the quarter. This raises concerns about financial sustainability if revenue generation does not improve.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expectation to start breaking business benefits of strategic shift: Evogene expects to start realizing the business benefits of its strategic shift towards computational chemistry and generative design of small molecules for pharmaceuticals and agriculture over the coming year.
ChemPass AI development: Evogene is advancing a multiyear development program for ChemPass AI, continuously adding new capabilities to improve precision and address more parameters. The system is expected to become smarter and more accurate with increased usage.
Collaboration with Google Cloud: Evogene plans to continue collaborating with major technology companies like Google Cloud to accelerate ChemPass AI development and explore making parts of its technology accessible to researchers.
AgPlenus' future plans: AgPlenus aims to strengthen and expand collaborations with existing partners, establish new partnerships, and broaden its internal development portfolio. These initiatives are expected to generate cash inflows through upfront payments, R&D reimbursements, milestone payments, and potential royalties.
Pharma division collaborations: Evogene's Pharma division plans to announce additional collaborations over the coming year, focusing on leveraging ChemPass AI for small molecule drug development. These partnerships aim to co-develop innovative products and generate revenue through R&D fees, milestone payments, and revenue-sharing mechanisms.
Expansion in agriculture and pharma: Evogene plans to expand collaborations with leading ag-chem companies and grow AgPlenus' internal crop protection pipeline. In pharma, the company aims to partner with biotech and pharmaceutical companies to develop small molecule-based drugs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Has the levels of interest in AI ChemPass increased post the recent NVIDIA and Eli Lilly AI drug discovery partnership? Also, could you please elaborate why Evogene's proprietary database should garner similar interest from others in pharma and technology industries?
A:Ofer Haviv stated that the NVIDIA and Eli Lilly announcement has increased interest in AI-related activities in the pharma industry, but Evogene was already generating interest due to its unique offerings. He highlighted Evogene's multiparameter approach, its team of PhD-level experts, and its collaboration with Google to create a dedicated AI engine for small molecule discovery and optimization. He also emphasized the company's tailored approach for each partner, which sets it apart from competitors.
Q:How close are you to unlocking partners with AI ChemPass?
A:Ofer Haviv mentioned that interest in AI ChemPass has significantly increased, with a growing list of potential candidates. He expects to announce new collaboration agreements with small biotech companies, academic institutions, and eventually midsized biotech and pharma companies, starting early next year.
Q:Last quarter, you spoke to doing more IR to drive awareness to the company, but very little seems to be done. What's the IR strategy going forward? And can we rely on it being implemented in short order?
A:Ofer Haviv acknowledged the delay in implementing the IR strategy but stated that the company is now focusing on presenting its new structure and strategy, particularly around ChemPass AI. He mentioned plans for roadshows, conferences, and professional events starting in December to increase awareness.
Q:Could you highlight upcoming catalysts over the coming 6 to 12 months? Specifically, when could we expect the first partnership?
A:Ofer Haviv outlined three types of press releases expected: new collaborations in the Pharma division, expansion or new collaborations in the Ag division, and partnerships with major companies like Google to accelerate ChemPass AI development. He expects announcements of small biotech collaborations early next year.
Q:What type of revenue level can we expect for castor seeds in Q4 and for 2026?
A:Ofer Haviv declined to disclose specific revenue levels but mentioned ongoing discussions with strategic companies in the castor oil field that could significantly impact future revenue. He noted that these discussions are progressing and will be shared once agreements are finalized.
Q:How excited are you about AI ChemPass compared to all your other times at Evogene?
A:Ofer Haviv expressed strong enthusiasm for AI ChemPass, stating that the pharma industry offers better financial opportunities compared to the ag sector. He emphasized the expertise of Evogene's team and the potential for significant achievements in the pharma industry, similar to their success in the ag sector.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue projections for castor seeds in Q4 and 2026, citing ongoing discussions with strategic companies. The response lacked numerical details and clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biomica
ChemPass AI
ICL
activity
agreement
agriculture
challenge
chemical
collaboration
company
discovery
drug
effort
income loss
income net
industry
line
molecule
month decrease
month period
net period
number
parameter
payment
period decrease
pharma
product development
protein
reduction
sale majority
subsidiary AgPlenus
success rate
tech engine
technology
trial
warrant
world
EVGN Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call reveals declining revenues, increased costs, and significant operating and net losses, indicating financial struggles. Despite cost reductions, the lack of clear guidance and vague responses during the Q&A, particularly regarding financial terms and timelines, adds uncertainty. The promising strategic shifts and partnerships, including with Google, are overshadowed by the immediate financial challenges. The market is likely to react negatively in the short term due to these concerns, leading to a predicted stock price movement in the negative range of -2% to -8%.
Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Positive11-20
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
EVGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
